Navigation Links
Hologic Announces Third Quarter Fiscal 2011 Operating Results
Date:8/1/2011

th in Breast Health revenues of $48.5 million, or 8.7%, driven by a $36.5 million, or 21.8%, increase in service revenue primarily related to our increased installed base of digital mammography systems; (ii) an increase in GYN Surgical revenues of $16.4 million, or 7.8%, primarily related to growth in sales of the Adiana system, as well as the inclusion of MyoSure and growth in sales of the NovaSure system; (iii) an increase in Skeletal Health revenues of $3.2 million, or 4.8%, primarily due to an increase in bone densitometry sales; and (iv) an increase in Diagnostics revenues of $3.0 million, or 0.7%, primarily from growth in revenues from our Cervista HPV tests that was partially offset by a decrease in ThinPrep revenues.

For the nine months ended June 25, 2011, Hologic reported net income of $129.6 million, or $0.49 per diluted share, compared with net income of $74.2 million, or $0.28 per diluted share, in the nine months ended June 26, 2010. The Company's non-GAAP adjusted net income increased 6.8% to $244.3 million, or $0.92 per diluted share, in the nine months ended June 25, 2011 compared to $228.7 million, or $0.87 per diluted share, for the same period in the prior year. The Company's non-GAAP adjusted net income for the first nine months of fiscal 2011 and 2010 primarily excludes: (i) a charge of $175.3 million and $171.3 million, respectively, attributable to the amortization of intangible assets; (ii) a non-cash interest expense charge of $54.4 million in each period related to the Company's Convertible Notes; and (iii) $4.1 million and $0.8 million, respectively, of acquisition-related costs and charges. The Company's non-GAAP adjusted net income for the first nine months of fiscal 2011 also primarily excludes: (i) an $84.5 million net gain, included as a credit within operating expenses, related to our agreement to sell the rights of the Makena (formerly Gestiva) assets to KV Pharmaceutical Company upon FDA approval in the first quarter;
'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- When someone gets sick, their first course of ... physician or an urgent care facility to receive treatment. ... by doctors and medical professionals comes from facilities such ... in every circumstance. Though it may seem counter intuitive, ... higher chances of contracting illnesses. Also, simply traveling to ...
(Date:3/2/2015)... MIAMI , March 2, 2015  Vivex Biomedical, ... patterning technology, and biocellular products, announced today that it ... Operating Officer of UMTB Biomedical, Inc.   Vivex Biomedical formed ... University of Miami Tissue Bank (UMTB) in November 2014. ... Mr. Barnes is a twenty-five year veteran ...
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
Breaking Medicine Technology:House Call Medicine Helps Patients Receive Treatment While Avoiding the Hassles and Potential Risks of an Urgent Care Facility 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3
... Calif., May 17 Essentialis Inc, a clinical ... its primary endpoint of statistically significant triglyceride reduction ... in dyslipidemic patients. The study encompassed both patients ... included normal weight, overweight and obese patients presenting ...
... analysis presented at 19th annual European Congress of Clinical ... , Finland SAN DIEGO, May 17 ... that the results from its North American Phase 3 ... difficile infection (CDI) were presented today by clinical ...
Cached Medicine Technology:Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US 2Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US 3Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection 2Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection 3Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection 4Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection 5
(Date:3/2/2015)... “ Wants and Needs ” was featured on NewsWatch ... latest and coolest mobile applications on the iOS, Android, ... and host of NewsWatch, conducted the app review and ... priorities. , Whether a person needs help re-orienting or ... app allows people to enter and track wants, both ...
(Date:3/2/2015)... Angeles, CA (PRWEB) March 02, 2015 ... offering gum reshaping procedures. Gum reshaping can involve one or ... or to regenerate lost gum tissue for a more even ... dark gum line treatment that can permanently lighten ... his total smile approach, which involves a personalized treatment plan ...
(Date:3/2/2015)... Va. (PRWEB) March 02, 2015 The ... nonprofit authority on the use of health IT to ... white paper, “ICD-10 Testing for Small Providers.” The white ... with a starting point for ICD-10 testing by focusing ... payers to ensure compliance with the October 1, 2015 ...
(Date:3/2/2015)... LegitScript, LLC, operator of ... including those for Internet pharmacy certification, monitoring ... classification, has launched a certification program for ... program, called iCareRx , provides certification ... identity of the owner/operator of Internet websites, ...
(Date:3/2/2015)... 2015 A true renaissance man—some might call ... 1960s cult rock band Khazad Doom, has long inspired his ... persevere despite all odds. His motto throughout his life has ... or goal was before him. And that attitude, born amidst ... passed on to a new generation. , As Eadon knows, ...
Breaking Medicine News(10 mins):Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3
... a mirror of the inner self. However, according to a new ... stroke-related death. // ,The study, published in the October ... the eyes to determine whether people have a higher risk of ... tiny lesions on the back of the eye are two to ...
... A new study published in the October 17 issue of ... fight inflammation in the gut. This feature may help the ... a foreign particle//. ,Fat rich foods stimulate the ... hormone called cholecystokinin, or CCK. This enzyme is responsible for ...
... elbow has been enjoying the spot light following ace cricketer ... However, the condition is not uncommon in the sports arena//. ... called in medical parlance, is an affliction where the outer ... a result of a specific strain, overuse or a direct ...
... for cardiovascular disease in both men and women, which ... subjects and that 80 percent of all type 2 ... In these patients hyperglycemia per se confers ... of even borderline-high-risk LDL-C signals the need for more ...
... out the benefits of oral ZYVOX for the treatment ... They compared data from 80 health care clinics and ... Vancomycin. The results show that oral tablets of Linezolid ... spent to health clinics compared to vancomycin. ...
... Terminally ill people have the right to a life of ... the pain which often accompanies diseases like cancer, say experts ... // . ,Currently, only a few states like Kerala, ... have provisions that allow care-giving organisations to administer strong pain ...
Cached Medicine News:Health News:Lesions in the eyes may forecast a stroke 2Health News:Tennis elbow not new among cricketers, say experts 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2Health News:Terminally Ill deserves a better quality of Life 2Health News:Terminally Ill deserves a better quality of Life 3
A portable, easy to use, dual-channel laser-Doppler tissue perfusion and temperature monitoring system, at a remarkably affordable price....
... high performance laser doppler system for ... blood perfusion. This latest generation single-channel ... with its multi-channel brother (Oxyflo), including ... and laser doppler flowmetry providing a ...
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
Medicine Products: